NCT01691209

Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis

An Investigator-blinded, Randomized, Monocentre, 3-arm, Active Controlled Pilot Trial to Explore the Efficacy and Safety of a Topical Medical Device in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With a Standard Therapy (1% Hydrocortisone Cream) and Untreated Skin

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The study shall explore whether treatment of atopic dermatitis is equally effective with Phoenix medical device as compared to standard therapy (Hydrocortisone cream).

Conditions

• Dermatitis, Atopic

Interventions

Type	Name	Description
DEVICE	Phoenix (BAY81-2996)	Topical formulation applied to the skin
DRUG	1% Hydrocortison cream	1% Hydrocortison cream applied to the skin

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-04-01
• Completion: 2014-06-01
• First posted: 2012-09-24
• Last updated: 2013-08-13

Locations

1 site across 1 country: Germany